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several points can now be made, such as the banning 
of bismuth in several countries, including France, the 
need for a dual antibiotic association, due to increasing 
resistance rates of H .  pylori to metronidazole [l], and 
the therapeutic breakthrough provided by proton pump 
inhibitors (PPIs) in adults [2] as well as in children 131. 
In a previous study, we showed that PPIs in association 
with metronidazole and amoxycillin or macrolide 
yielded an eradication rate of 85.7% [3] to be compared 
to 100% [4] in a slightly earlier study. 
A recent trend seems to favor a new macrolide, 
namely clarithromycin, a molecule more acid-stable 
than erythromycin and with excellent activity in vitro, 
which provides an excellent eradication rate in adults 
[5] with a 1-week-duration treatment [2]. Recently, in 
children, a 2-week treatment combining clarithro- 
mycin with metronidazole and omeprazole provided 
an effective eradication rate of 93% with full com- 
pliance [6]. 
The purpose of this study was to investigate, 
through an open study, the potential of clarithromycin 
in association with amoxycillin and lansoprazole ad- 
ministered in a 1-week treatment in children with 
proven H. pylori gastric infection. 
The study involved 25 children, 19 girls and six 
boys, aged 13.5t2.6 years (range 8-16 years), with 
H. pylori gastric infection proved by endoscopic, 
histologic and/or culture samples. Culture was positive 
in 15, with H. pylori strains susceptible to amoxycillin 
in all, resistant to metronidazole in nine (60%), and 
resistant to clarithromycin in two (13.3%). Children 
were treated for 8 days with lansoprazole 1 mg/kg per 
day, maximum 30 mg, clarithromycin 7.5 mg/kg b.i.d. 
(twice daily), maximum 500 mg b.i.d. and amoxycillin 
50 mg/kg bid. ,  maximum 1 g b.i.d. As assessed by a 
13C[urea] breath test [7] performed 6 weeks following 
discontinuation of therapy, the infection was eradicated 
in 23 children (92%; 95% confidence interval, 0.11, 
0.36). Four children only exhibited transient side 
effects; two children exhibited vomiting and the other 
two had abdominal pain. Therapeutic compliance was 
excellent-that is, all the children took more than 90% 
of the drugs. H. pyIori infection was not eradicated in 
only two children. One exhibited primary clarithro- 
mycin-resistant strains and the other had a positive 
histology with a negative culture, preventing any deter- 
mination of sensitivity to antibiotics. Furthermore, 
H. pylori infection was also eradicated in the second child 
who exhibited primary clarithromycin-resistant strains. 
This study underlines an excellent eradication rate 
with the proposed short-term triple association and 
further assesses the increasing rate of metronidazole 
resistance of H. pylori strains, contrasting with the low 
rate observed with clarithromycin. 
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We were interested to read the recent article by 
Clevenberg et al [l] regarding the frequency ofhepatitis 
G/GB virus (HGV) infection. In that study they found 
four of 100 HIV-infected patients to be viremic with 
HGV by PCR, and 31 of 100 to be positive for HGV 
antibody as measured by an immunoassay directed 
against the E2 epitope of the virus. They also com- 
mented on an apparent relationship between lamivudine 
therapy and loss of HGV viremia. This was based on a 
high proportion (26/31) of the anti-E2 antibody 
patients having received antiretroviral agents, including 
lamivudine. None of their four patients with detectable 
HGV sequences in plasma received lamivudine at the 
initial time of testing, although three did subsequently 
and one lost HGV signal by PCR. 
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This prompted us to review our own study of 192 
AIDS patients, and the relationship between lamivudine 
therapy and the results of HGV PCR testing and anti- 
E2 antibody testing [2].  In that study, SO (36%) of the 
samples were positive for HGV antibody and 44 (32%) 
were positive for HGV RNA. A similar prevalence of 
HGV P C R  positivity (22%) has been described in the 
USA [3],  in Japanese with hemophilia (27%) [4], in 
Italian HIV-infected mothers (21%) [5] and in German 
HIV patients (17%) [6]. 
In our cohort of patients, tested shortly after the 
widespread introduction of lamivudine in HIV therapy, 
110 had received lamivudine. Of these, 34 (31%) 
were antibody positive for HGV, 28 (26%) had HGV 
sequences in plasma by PCR,  and the remaining 58 
(53%) were negative on testing for both. Of  those who 
had not received lamivudine, 16 (20%) had antibodies 
to HGV, 15 (18%) had HGV sequences in plasma by 
P C R  and the remainder (SO% or 61%) were negative 
in both tests. There appeared, therefore, to be no clear 
protective benefit of lamivudine. Furthermore, of 
those who received lamivudine, those who had HGV 
sequences in plasma received a mean of 135 days of 
treatment with that drug versus 130 days for those who 
had antibody in plasma and 132 days for those who had 
negative results for both tests. Thus, in this large 
retrospective study, we could find no evidence support- 
ing an effect of lamivudine on the prevalence of HGV 
infection as determined by the presence of viral 
sequences in plasma. Additionally, though such an 
effect could come about through immune reconstitution 
or a direct antiviral response, it is noteworthy that 
antiretroviral therapy regimens including lamivudine 
do not decrease levels of the HGV-related hepatitis C 
virus [7]. 
It  is unclear why the Clevenberg study found such 
a low prevalence of HGV in their HIV-infected 
population. The populations in earlier studies [2-61 
varied in their risk factors, but all risk groups are well 
represented in this study, with the exception of trans- 
fusion-related HIV infection [ 11. Approximately a third 
were intravenous drug users, or had homosexually or 
heterosexually acquired disease. A similar mixed popu- 
lation was included in some other studies [2,3,6]. There 
is also no clear unfavorable relationship between HGV 
positivity by P C R  and CD4 count or HIV status 
(indeed, it may be a marker of improved prognosis in 
HIV [4,6,8]. Alternative explanations for the difference 
in results might be different sensitivities of the assays 
used to detect viral sequences, local variation in the 
virus genome, or cross-reactivity with another, more 
immunogenic, local virus leading to higher than other- 
wise seen rates of seroconvtrsion and consequent 
antibody production. However, it appears clear from 
the results of our study that treatment with lamivudine 
is unlikely to explain the low prevalence of HGV 
infection in the Clevenberg study. Fortunately, it is our 
current understanding that there is presently no  
indication for treatment of persons infected with HGV. 
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